QBI presents a seminar with Zach Sweeney, who focuses on therapeutic discovery at QBI. Zach is formerly the CEO and co-founder of Interline Therapeutics and a Venture Partner at ARCH Venture Partners and Foresite Labs. He has broad experience growing and leading successful multifunctional drug discovery groups, including small molecule, biotherapeutic, and AAV discovery platforms.

He was also previously the Chief Scientific Officer at Denali Therapeutics, where he led the growth of the discovery portfolio and research group. Prior to joining Denali, Zach was a leader in the drug discovery groups at Revolution Medicines, Novartis, Genentech, and Roche. Approximately a dozen molecules that Zach and his teams have developed at these companies have progressed into clinical studies, and these potential medicines have been the subject of major licensing deals that cumulatively generated more than $1B in upfront payments.

He received a B.S. degree in Chemistry at Stanford University. He subsequently earned a Ph.D. in Chemistry from the University of California, Berkeley, and completed a NIH postdoctoral fellowship at Harvard University. Zach’s research interests include the application of genomic and biomarker information in drug discovery, computational chemistry and structural biology, and the chemical biology of drug candidates. He is listed as an inventor on 60 published patent applications and has co-authored more than 40 scientific publications.

Talk Title: New drug candidates for neurodegenerative and inflammatory diseases enabled by convergent proteogenomic networks 

Host: Nevan Krogan